Efficacy and Safety of Avutometinib ± Defactinib in Recurrent Low-Grade Serous Ovarian Cancer: Primary Analysis of ENGOT-OV60/GOG-3052/RAMP 201.
Susana N Banerjee, Els Van Nieuwenhuysen, Carol Aghajanian...
https://pubmed.ncbi.nlm.nih.gov/40644648/Actively Recruiting
Led by Verastem, Inc. · Updated on 2026-11-02
270
Participants Needed
105
Research Sites
121 weeks
Total Duration
Researchers are evaluating the safety and effectiveness of a combination of two investigational drugs, avutometinib and defactinib, compared to standard treatments chosen by doctors in patients with recurrent low-grade serous ovarian cancer LGSOC who have progressed after prior platinum-based therapy. This Phase 3, international, randomized, open-label study aims to compare progression-free survival and also assess overall survival, safety, quality of life, and disease symptoms. The study is conducted by specialists in gynecological cancer. Participants will receive either the combination of avutometinib and defactinib or one of four standard treatments recommended for recurrent LGSOC. Avutometinib is given orally at 3.2 mg twice weekly for 21 days followed by 7 days off in a 28-day cycle, combined with defactinib given orally at 200 mg twice daily on the same schedule. The standard treatments include pegylated liposomal doxorubicin, paclitaxel, anastrozole, or letrozole, each administered according to their usual dosing schedules. Patients initially receiving standard treatment who experience disease progression may switch to the investigational drug combination. During the study, participants will have regular visits for treatment and follow-up assessments including laboratory tests and evaluations of tumor status. Researchers will monitor progression-free survival for up to 24 months and overall survival for up to 5 years. They will also assess response rates, duration of response, disease control, adverse events, blood drug levels, and quality of life using questionnaires. The total study duration may extend until 2031, with ongoing monitoring of health and symptoms throughout.
CONDITIONS
A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer
V
Verastem Call Center
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Verastem, Inc.
Lead Sponsor
GOG Foundation
Collaborating Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | Avutometinib + Defactinib (Investigational) | Investigator’s Choice Treatment (Active Comparator) |
|---|---|---|
| What it is | Combination of oral MEK inhibitor avutometinib and oral FAK inhibitor defactinib | Therapy chosen by the investigator among pegylated liposomal doxorubicin, paclitaxel, letrozole, or anastrozole |
| Role in trial | Investigational therapy evaluated in crossover design | Active comparator arm using standard treatments per physician choice |
| Primary use | Treatment of recurrent low‑grade serous ovarian cancer in patients with prior therapy | Alternative treatment options used clinically after recurrence |
| How it is given or performed | Both drugs are taken orally | Administered as per drug: liposomal doxorubicin or paclitaxel intravenously, letrozole or anastrozole orally |
| Evidence status | Efficacy under investigation; results not yet available | Commonly used options in recurrent LGSOC but not strongly evidence‑based due to disease rarity |
| Important risks | Risks not yet established in clinical outcomes | Known chemotherapy and hormonal therapy risks vary by agent |
| Important limitations | Unknown effectiveness and tolerability; early clinical investigation | Limited efficacy in LGSOC due to poor chemotherapy sensitivity and lack of high‑quality evidence |
| Patient impact | Impact not yet known, as outcomes pending | Limited benefit expected based on poor chemotherapy response in LGSOC |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 24 months
Participants receive either the combination of avutometinib plus defactinib or one of several standard treatments chosen by their doctor. Those on standard treatment who experience disease progression may switch to the investigational drugs.
Regular visits during treatment cycles
Duration - Up to 5 years
Participants are monitored for overall survival, response to treatment, adverse effects, and quality of life.
Periodic follow-up visits
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
CROSSOVER
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Susana N Banerjee, Els Van Nieuwenhuysen, Carol Aghajanian...
https://pubmed.ncbi.nlm.nih.gov/40644648/Rachel Grisham, Bradley J Monk, Els Van Nieuwenhuysen...
https://pubmed.ncbi.nlm.nih.gov/39375168/Susana N Banerjee, Els Van Nieuwenhuysen, Carol Aghajanian...
https://pubmed.ncbi.nlm.nih.gov/41384753/Verastem, Inc.
Lead Sponsor
GOG Foundation
Collaborating Sponsor